舒肝和胃饮治疗肝胃不和型胆汁反流性胃炎的临床观察

发布时间：2018-10-08 14:13

【摘要】：研究目的：本课题在中医辨证理论的指导下,研究舒肝和胃饮联合奥美拉唑、莫沙必利对肝胃不合型胆汁反流性胃炎的临床疗效,观察其在缓解临床症状、胃镜下胆汁反流、改善病人的生活质量方面是否具有优势,为本病的临床治疗提供借鉴。研究方法：挑选符合中医和西医诊断标准的胆汁反流性胃炎患者40例,随机将40例患者分为治疗组20例(服用舒肝和胃饮、奥美拉唑肠溶胶囊、枸橼酸莫沙必利)和对照组20例(服用奥美拉唑肠溶胶囊和枸橼酸莫沙必利)。治疗前后分别采用胃镜评估和问卷调查方式了解其临床症状和胆汁反流严重程度,疗程为8周,疗程结束后,分别对两组患者在治疗前后的中医证候积分、单项症状积分、胃镜下疗效进行统计学分析。研究结果：治疗组总体有效率达95%,对照组的总体有效率为70%,经过统计学分析比对,治疗组较对照组有效,且具有显著性差异P0.05。治疗后两组患者中医证候积分均有下降,差异具有显著性P0.05,证明治疗组和对照组的治疗均有效果；中医证候积分方面,治疗组前后差值高于对照组,且经统计学分析,具有显著性差异P0.05,证明治疗组在对于中医症状方面的改善疗效优于对照组。单项症状方面,两组治疗后各症状均有明显改善P0.05,治疗组在改善患者反酸、脘腹胀痛、呃逆、嗳气、情志抑郁、食纳不振、善太息方面方面疗效更为显著P0.05。胃镜下胆汁反流情况方面,治疗组总有效率达95%,对照组总有效率为65%,经统计学分析比对,具有显著性差异P0.05。结论：舒肝和胃饮治疗肝胃不和型胆汁反流性胃炎的临床疗效显著。
[Abstract]:Objective: to study the clinical effect of Shugan and Weiyin combined with omeprazole and mosapride in the treatment of hepatogastric incompatibility bile reflux gastritis, and to observe its clinical symptoms and bile reflux under gastroscopy, under the guidance of TCM syndrome differentiation theory, the clinical effect of Shugan and Weiyin combined with omeprazole and mosapride was studied. Improve the quality of life of patients whether there are advantages for the clinical treatment of this disease to provide reference. Methods: forty patients with bile reflux gastritis who met the diagnostic criteria of traditional Chinese medicine and western medicine were selected and randomly divided into treatment group (20 cases) (taking Shugan and Wei Yin and omeprazole enteric capsule). Mosapride citrate and 20 patients in control group were treated with omeprazole enteric capsule and mosapride citrate. Before and after treatment, the clinical symptoms and the severity of bile reflux were evaluated by gastroscopy and questionnaire. The course of treatment was 8 weeks. After the course of treatment, the TCM syndromes and single symptom scores of the two groups before and after the treatment were separately analyzed. The curative effect under gastroscope was analyzed statistically. Results: the total effective rate of the treatment group was 95 and the total effective rate of the control group was 70. After statistical analysis and comparison, the treatment group was more effective than the control group, and the difference was significant (P 0.05). After treatment, the TCM syndromes scores of the two groups were decreased, and the difference was significant (P0.05), which proved that the treatment group and the control group were effective, the difference of TCM syndrome score in the treatment group was higher than that in the control group, and the difference between the two groups was higher than that in the control group, and the difference between the two groups was statistically analyzed. There was significant difference (P0.05), which proved that the therapeutic effect of the treatment group was better than that of the control group in improving TCM symptoms. In the single symptom aspect, each symptom of the two groups was obviously improved (P0.05) after treatment. The curative effect of the treatment group was more remarkable in improving the patients' regurgitation, abdominal distending pain, hiccup, belching, emotional depression, poor food intake and good information (P0.05). In the case of bile reflux under gastroscope, the total effective rate of the treatment group was 95%, and the total effective rate of the control group was 65%. There was a significant difference between the two groups (P0.05). Conclusion: Shugan Hewei Yin is effective in the treatment of hepatogastric disharmony bile reflux gastritis.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】